BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 18, Issue 5
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2026; 18(5): 118508
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.118508
Survival gap in gallbladder cancer: Bridging tumor biology and healthcare system logistics
Bruno Mirandola Bulisani
Bruno Mirandola Bulisani, Department of Digestive Surgery, Centro Universitário FMABC, Santo André 09060-870, São Paulo, Brazil
Author contributions: Bulisani BM wrote the manuscript, conducted the critical literature review, designed the figure, and approved the final version.
Conflict-of-interest statement: The author declares that there are no conflicts of interest related to this work.
Corresponding author: Bruno Mirandola Bulisani, MD, MSc, Department of Digestive Surgery, Centro Universitário FMABC, Avenida Lauro Gomes, 2000, Santo André 09060-870, São Paulo, Brazil. brunomirandola@hotmail.com
Received: January 12, 2026
Revised: February 6, 2026
Accepted: April 22, 2026
Published online: May 27, 2026
Processing time: 142 Days and 10.7 Hours
Core Tip

Core Tip: Gallbladder cancer (GBC) prognosis is traditionally viewed through the lens of aggressive tumor biology. However, in intermediate-incidence regions like Brazil, systemic fragmentation often prevents curative intent. This opinion review proposes a paradigm shift: Classifying healthcare logistics as a modifiable prognostic factor. By integrating molecular stratification, focusing on TP53 and HER2, with logistical “auto-alerts” and neoadjuvant “biological filters”, we can bridge the survival gap. Optimizing the “therapeutic window” between incidental diagnosis and radical surgery is as crucial as the surgical technique itself in transforming GBC outcomes.
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.